Fact CheckerSign in

NCT05539794Recruiting

Exercise in Adolescents With Cancer

Exercise Intervention for Adolescents With Cancer (EXERCADOL): A Randomized Controlled Trial

Source: ClinicalTrials.gov · Last updated 22 Jul 2026

Brief summary (registry, in English)

The investigators will study the effects of an supevised exercise intervention along the duration of intensive treatment (neoadjuvant \[solid tumours\]/intense chemotherapy \[leukemias\], expected median duration 5-6 months) on several health-related variables. Participants will be recruited from 4 hospitals in Madrid (Spain). Inclusion criteria: male/female aged 12-19 years, newly diagnosed--or relapse of-- a malignant extracranial tumour; not having received any type of therapy--except surgery--at the time of diagnosis; adequate health status (Karnofsky/Eastern Cooperative Oncology Group scale score ≥50/≤2); to understand Spanish language and to provide written informed consent. The investigators will recruit ≥136 participants and conduct a randomised controlled trial. The intervention group will follow a supervised concurrent exercise program from the start to the end of intensive treatment. The exercise intervention will be performed in the hospital gymnasium or in the patients' ward (during neutropenic phases), and will also include supervised online sessions. Additionally, the intervention group will perform include inspiratory muscle training. The following outcomes will be assessed at baseline (diagnosis), end of treatment, and at 3-month follow-up in all participants: echocardiography-determined left ventricular function (primary outcome); and other echocardiography-determined variables, cardiac biomarkers, blood pressure, blood lipids, body composition, physical activity levels, energy intake, cardiorespiratory fitness, muscle strength, functional mobility, health-related quality of life, cancer-related fatigue, clinical variables, and potential biological underpinnings of exercise multisystemic benefits (metabolic and inflammatory markers, plasma proteome, gut microbiome, and immune function).

Status (registry)
Recruiting
Study type
Interventional
Enrollment
136 (estimated)
First submitted
18 Apr 2022
Start date
15 Apr 2022
Primary completion date
31 Dec 2026
Lead sponsor
Universidad Europea de Madrid
NCT number
NCT05539794

What you commit to

  • Study type: Interventional
  • Planned participants: 136
  • From 15 Apr 2022 to the primary completion date, 31 Dec 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Comorbidity/acute condition contraindicating exercise practice

Other

  • Life expectancy \<3 months

Who the study is looking for

  • Newly diagnosed with a malignant extracranial tumour
  • Not having received any therapy--except surgery--at diagnosis
  • Adequate health status (Karnofsky/Eastern Cooperative Oncology Group scale score ≥50/2)
  • To understand Spanish language and provide written informed consent.

Age in the registry: 12 years to 19 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
UEM
Coordinator of this site? Confirm its status
MadridSpainRecruiting
Universidad Europea de Madrid
Coordinator of this site? Confirm its status
Villaviciosa de OdónSpainRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.